Efalizumab

Bibliography

• Griffiths CE, Iaccarino L, Naldi L, Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006;24(Suppl 40):S72-8
   PubMed Web of Science ®Google Scholar
• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl 2):ii18-23
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Krueger JG, Bright R, Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;10(3):428-35
   Web of Science ®Google Scholar
• Papp K, Bissonnette R, Krueger JG, The treatment ofmoderate to severe psoriasis with a new anti-CD11a monoclonalantibody. J Am Acad Dermatol 2001;45(5):665-67
   PubMed Web of Science ®Google Scholar
• Jullien D, Prinz JC, Langley RG, T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004;208:297-306
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13
   PubMed Web of Science ®Google Scholar
• Goffe BS. Disseminated granuloma annulare resolved with the T-cell modulator efalizumab. Arch Dermatol 2004;140:1287-88
   PubMed Web of Science ®Google Scholar
• Clayton TH, Ogden D, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol 2006;54:892-95
   PubMed Web of Science ®Google Scholar
• Huber A, Gaffal E, Bieber T, Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol 2006;86:254-55
   PubMed Web of Science ®Google Scholar
• Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol 2006;142:555-8
   PubMed Web of Science ®Google Scholar
• Kaelin U, Hassan AS, Braathen LR, Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 2006;55:529-32
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Papp KA, Gordon KB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-33
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon K, Carey W, Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8
   PubMed Web of Science ®Google Scholar
• Dubertret L, Sterry W, Bos JD, Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a Phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-81
   PubMed Web of Science ®Google Scholar
• Sterry W, Stingl G, Langley RG, Clinical experience acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial. J Dtsch Dermatol Ges 2006;4:947-56
   PubMedGoogle Scholar
• Leonardi C, Menter A, Hamilton T, Efalizumab: results of a 3 year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107-16
   PubMed Web of Science ®Google Scholar
• Lotti T, Chimenti S, Katsambas A, Efficacy and safety of efalizumab in patients with moderate-to-severe plaque psoriasis resistant to previous anti-psoriatic treatment: results of a multicentre, open-label, Phase IIIb/IV trial. Arch Drug Inf 2010;3(1):9-18
   PubMedGoogle Scholar
• De Jong EM, Mork NJ, Seijger MM, The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003;148:318-25
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC, Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65
   PubMed Web of Science ®Google Scholar
• Shupack J, Abel E, Bauer E, Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997;36:423-32
   PubMed Web of Science ®Google Scholar
• Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, van de Kerkhof PC. Interruption of long-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995;75:393-6
   PubMed Web of Science ®Google Scholar
• Van Joost TH, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis: a double-blind study. Br J Dermatol 1988;118:183-90
   PubMed Web of Science ®Google Scholar
• Gulliver W. HLA-Cw6 polymorphism predict response to the biologic therapy efalizumab in patients with chronic plaque psoriasis. Presented at: 67th Annual Meeting of the American Academy of Dermatology. Presentation P3302; 2009; San Francisco, CA
   Google Scholar
• Costanzo A, Botti E, Papoutsaki M, Cw0602 allele is a potential predictor of response to efalizumab treatment in psoriasis. Presented at: 67th Annual Meeting of the American Academy of Dermatology. Presentation P3312; March 2009; San Francisco, CA
   Google Scholar
• Costanzo A, Spallone G, Talamonti M, New developments in the pharmacogenetics of psoriasis: HLA-Cw6 as a marker for the treatment of psoriasis with biological therapies. Adv Psoriasis Inflamm Skin Dis 2010;1(4):125-30
   Google Scholar
• Costanzo A, Peris K, Talamonti M, Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007;156(S2):17-23
   PubMed Web of Science ®Google Scholar
• Prignano F, Buggiani G, Lotti T. Efalizumab in the treatment of psoriasis: when comorbidity is an issue. Dermatol Ther 2008;21:S25-9
   PubMed Web of Science ®Google Scholar
• Gupta S, Tripathi CD. Current status of TNF blocking therapy in heart failure. Indian J Med Sci 2005;59:363-6
   PubMedGoogle Scholar
• Desai SB, Furst DE. Problems encountered duringanti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-90
   PubMed Web of Science ®Google Scholar
• Krueger G, Callis K. Potential of tumor necrosis factorinhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004;140:218-25
   PubMed Web of Science ®Google Scholar
• Jordan JK. Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother 2005;39:1476-82
   PubMed Web of Science ®Google Scholar
• Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26(1):6-14
   PubMed Web of Science ®Google Scholar
• Hamilton TK. Clinical considerations of efalizumab therapy inpatients with psoriasis. Semin Cutan Med Surg 2005;24:19-27
   PubMed Web of Science ®Google Scholar
• Costanzo A, Talamonti M, Spallone G, Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy. Dermatology 2009;218(2):146-50
   PubMed Web of Science ®Google Scholar
• Papp KA, Bressink R, Fretzin S, The safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a Phase IIIb, randomized controlled trial. Int J Dermatol 2006;45:605-14
   PubMed Web of Science ®Google Scholar
• Menter A, Kardatzke D, Rundle AC, Incidence and prevention of rebound upon efalizumab discontinuation. International Psoriasis Symposium 2004 (Toronto, CDN, 2004); 2004
   Google Scholar
• Papp K, Toth D, Rosoph L. Investigational study comparing different transitioning therapies for patients discontinuing treatment with efalizumab. 14th EADV Fall Symposium (London, UK; 12 – 16 October 2005); 2005
   Google Scholar
• Schmitt-Rau K, Jahn S. Efalizumab (Raptiva). In: Dubel S, editor, Handbook of therapeutic antibodies; 2007
   Google Scholar
• Papp KA, Bressink R, Fretzin S, The safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a Phase IIIb, randomized controlled trial. Int J Dermatol 2006;45:605-14
   PubMed Web of Science ®Google Scholar
• Dubertret L, Sterry W, Bos JD, Clinical experience aquired with the efalizumab (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a Phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-81
   PubMed Web of Science ®Google Scholar
• Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis durino treatment with efalizumab. A case report. Acta Derm Venereol Suppl (Stockh) 2006;86:456-7
   Google Scholar
• Pincelli C, Henninger E, Casset-Semanaz F. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab. Arch Dermatol Res 2006;298:329-38
   PubMed Web of Science ®Google Scholar
• Pincelli P, Casset-Semanez F. Efalizumab therapy and incidence of arthropathy adverse events: analysis of pooled data from Phase II, III, IV clinical trials. Psoriasis—from gene to cliic. 4th internationalcongress. (London, UK; 1 – 3 December 2005); 2005
   Google Scholar
• Martin B, Sanchez-Carazo JL, Perez-Ferriols A, Delayed generalized inflammatory psoriasis flare during efalizumab treatment. Br J Dermatol 2009;161(1):212-13
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK, Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Trying SK, Hamilton TK, A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13
   PubMed Web of Science ®Google Scholar
• Raptiva [efalizumab] prescribing information. Genentech, Inc. South SanFrancisco (CA); 2005
   Google Scholar
• Warkentin T, Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 2005;143:761-3
   PubMed Web of Science ®Google Scholar
• Hostetler SG, Zirwas M, Bechtel MA. Efalizumab-associated thrombocytopenia. J Am Acad Dermatol 2007;57(4):707-10
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Hamilton T, Caro I, Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54(Suppl):S154-63
   PubMed Web of Science ®Google Scholar
• Leonardi C, Papp K, Gordon K, Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J Am Acad Dermatol 2005;52:425-33
   PubMed Web of Science ®Google Scholar
• Warkentin T, Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 2005;143:761-3
   PubMed Web of Science ®Google Scholar
• Anonymous. In: Raptiva (efalizumab). Dermatologic and ophthalmologic drugs advisory committee meeting; 9 September 2003; Genetech, Inc., South San Francisco, CA
   Google Scholar
• Leonardi C. Efalizumab in the treatment of psoriasis. Dermatol Ther 2004;17:393-400
   PubMedGoogle Scholar
• Jordan JK. Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother 2005;39:1476-82
   PubMed Web of Science ®Google Scholar
• Package insert. Raptiva (efalizumab). Genentech, San Francisco; 2005
   Google Scholar
• Tom WL, Miller MD, Hurley MY, Efalizumab-induced autoimmune pancytopenia. Br J Dermatol 2006;155:1045-7
   PubMed Web of Science ®Google Scholar
• Aster RH. Drug-induced immune cytopenias. Toxicology 2005;209:149-53
   PubMed Web of Science ®Google Scholar
• Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005;23:247-50
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Leitch HA, Vickars LM, Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003;71:396-8
   PubMed Web of Science ®Google Scholar
• Philippeaux MM, Vesin C, Tacchini-Cottier F, Piguet PF. Activated human platelets express beta2 integrin. Eur J Haematol 1996;56:130-7
   PubMed Web of Science ®Google Scholar
• Leonardi C, Toth D, Cather JC, A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006;213:204-14
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209
   PubMed Web of Science ®Google Scholar
• Lindelo B, Sigurgeirsson B, Tegner E, PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141:108-12
   PubMed Web of Science ®Google Scholar
• Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: nested cohort crossover study. Lancet 2001;358:1042-5
   PubMed Web of Science ®Google Scholar
• Bommakanti S, Patil A, Eshoa C, Chitambar CR. Case reports: efalizumab-associated lymphoproliferative disease. J Drugs Dermatol 2007;6:646-8
   PubMedGoogle Scholar
• MacKenzie P, Kamili QU, Menter A, Cooper B. Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy. Clin Lymphoma Myeloma Leuk 2010;10(1):E14-16
   PubMed Web of Science ®Google Scholar
• Hernandez C, Worobec SM, Gaitonde SS, Progression of undiagnosed cutaneous T-Cell lymphoma during efalizumab therapy. Arch Dermatol 2009;145:92-4
   PubMed Web of Science ®Google Scholar
• Langley RG, Carey WP, Rafal ES, Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005;27(9):1317-28
   PubMed Web of Science ®Google Scholar
• Kirby B, Griffiths CE. Psoriasis: the future Br J Dermatol 2001;144(Suppl 58):37-43
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr, Auerbach R, Maibach H, Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003;29:185-202
   PubMed Web of Science ®Google Scholar
• Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63
   PubMed Web of Science ®Google Scholar
• Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000;343:37-49
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357:1842-6
   PubMed Web of Science ®Google Scholar
• Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept. Arch Dermatol 2006;142:151-2
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Off-label uses and side effects of infliximab. J Drugs Dermatol 2004;3:273-84
   PubMedGoogle Scholar
• Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003;30:407-11
   PubMed Web of Science ®Google Scholar
• Langley RG, Carey WP, Rafal ES, Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005;27(9):1317-28
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Gordon KB, Hamilton TK, Leonardi C. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe plaque psoriasis: final Phase IIIb study results. J Am Acad Dermatol 2005;52:4
   Web of Science ®Google Scholar
• Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects [review]. Expert Opin Drug Saf 2006;5(2):197-209
   PubMed Web of Science ®Google Scholar
• Kluger N, Girard C, Gonzalez V, Efalizumab-induced aseptic meningitis. Br J Dermatol 2007;156(1):189-91
   PubMed Web of Science ®Google Scholar
• Rivas-Rodriguez R, Romero-Alonso MM, Gabella-Bazarot E, Efalizumab-induced aseptic meningitis. Farm Hosp 2007;31(1):70-1
   PubMedGoogle Scholar
• Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med 1999;159:1185-94
   PubMed Web of Science ®Google Scholar
• Tian L, Kilgannon P, Yoshihara Y, Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte integrin CD11a/ CD18. Eur J Immunol 2000;30:810-18
   PubMed Web of Science ®Google Scholar
• Barron H. Important drug warning regarding Raptiva (Efalizumab). October 2008. Available from: http://www.gene.com/gene/products [14 January 2009]
   Google Scholar
• Balato A, Balato N, Balato Y, Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008;217:360-1
   PubMed Web of Science ®Google Scholar
• Weisenseel P, Kuznetsov AV, Flaig M, Prinz JC. Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. Dermatology 2008;217:85-6
   PubMed Web of Science ®Google Scholar
• Caudron A, Lok C, Clabaut A, Cytomegalovirus colitis in a patient treated with efalizumab. Dermatology 2009;218(1):84-5
   PubMed Web of Science ®Google Scholar
• Zu Rhein GM. Polyoma-like virions in a human demyelinating disease. Acta Neuropathol 1967;8:57-68
   PubMed Web of Science ®Google Scholar
• Cavanagh JB, Greenbaum D, Marshall AB, Rubinstein LJ. Cerebral demyelination associated with disorders of the reticuloendothelial system. Lancet 1959;2:524-9
   PubMed Web of Science ®Google Scholar
• Padgett BL, Walker DL, Zu Rhein GM, Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:1257-60
   PubMed Web of Science ®Google Scholar
• Eng PM, Turnbull BR, Cook SF, Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 2006;67:884-86
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-68
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40
   PubMed Web of Science ®Google Scholar
• Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145:937-42
   PubMed Web of Science ®Google Scholar
• Genentech. Important safety information, October 2008
   Google Scholar